Insulin Delivery Devices Market- Evolving Market Trends

Global Insulin Delivery Devices Market: Snapshot

The demand in the global insulin delivery devices market is projected to increment at a robust CAGR of 8.6% during the forecast period of 2017 to 2025, gaining traction from a number of factors, but none bigger than the prevalence of diabetes, which is a highly common chronic disease that affected about 8.5 of the global population in 2014, according to the figures provided by the World Health Organization (WHO). Advancements in insulin delivery devices with improving technology, government initiatives to impart awareness, and appreciative reimbursement environment in a number of developed countries are some of the other factors favoring the global insulin delivery devices market. On the other hand, the lack of awareness regarding the availability of alternative insulin delivery methods such as oral and poor reimbursement policies in a number of developing countries are hindering the market from achieving its true potential.

View Report @ http://www.transparencymarketresearch.com/insulin-delivery-devices-market.html

As per the estimations of this report, the global insulin delivery devices market will be worth US$20,996.2 mn by the end of 2025, notably up from its evaluated valuation of US$10,160 mn in 2016. While insulin pens is the most in-demand product segment, North America is most profitable regional market. Escalated research and development activities regarding diabetes-case is expected to open new revenue avenues for the vendors operating in the global insulin delivery devices market.

Insulin Pens Make Highly Profitable Product Segment

The global insulin delivery devices market, on the basis of product, has been segmented into insulin pens, insulin syringes, insulin pumps, needle-free injection jet, and insulin patches. Among these, insulin pens segment accounted for 42% of the total demand in 2016, and is projected to remain the most profitable product segment throughout the forecast period. This sustained demand for insulin pens is owing to its high adoption in the vastly populated region of Asia Pacific, along with the developed region of Europe. In these two regions, nearly 90% of the diabetic patients use insulin pens, a device that has not penetrated as much into the developed country of the U.S., wherein only 25% of the population use the product. That being said, the popularity of insulin pens is expected to increment steadily in the U.S. in the near future as its advantages such as flexibility and moderate pain.

North America and Europe Serve Maximum Demand

Out of the five regions studied by this report: North America, Asia Pacific, Europe, Latin America, and The Middle East and Africa, the insulin delivery devices market currently has the maximum potential in North America, which served 37.5% demand in 2016. Most of the demand from North America comes from the country of The U.S., which has diabetes spread across the masses along with a robust healthcare infrastructure. 

Get accurate market forecast and analysis on the Insulin Delivery Devices Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=29459

Mushrooming private diabetic care facilities, well-defined reimbursement policies, and growing awareness are some of the other factors augmenting the demand in the North America insulin delivery devices market. While Europe is currently the second most profitable region for the vendors operating in the global insulin delivery devices market, vastly populated Asia Pacific is expected to turn into a highly lucrative region towards the end of the forecast period, gaining solid demand from the emerging economies such as India and China.

Some of the key companies operating in the global insulin delivery devices market are: Sanofi S.A., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., B. Braun Melsungen AG, Eli Lilly and Company, Medtronic plc, Becton, Dickinson and Company, Cellnovo Group SA., Owen Mumford Ltd., Biocon Ltd., Animas Corporation (Johnson & Johnson), and Tandem Diabetes Care, Inc. Currently, the competitive landscape of insulin delivery devices market is quite fragmented with the presence of a number of local vendors.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.